Patient Access & Affordability
  • About
    • Mission
    • Who We Are
    • Advisory Board
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
      • Featured Work
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page
This controversial health regulator thinks RA is just “morning stiffness” and “joint swelling”

This controversial health regulator thinks RA is just “morning stiffness” and “joint swelling”

Jan 9, 2020

A new report on rheumatoid arthritis treatments published by a controversial cost appraiser is facing strong criticism from patient advocates, who say it minimizes the autoimmune disease as simply “morning stiffness” and “joint swelling”. The Institute for Clinical...

Scoping Document for ICER Review of Drugs for Rheumatoid Arthritis Posted for Public Comment

Aug 3, 2016

–Document will inform development of report for public deliberation by the Midwest CEPAC– August 1, 2016 – The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for rheumatoid arthritis....

Categories

  • Access & Affordability
  • Blog
  • Comments
  • ICERWatch
  • News
  • Opinion
  • QALY
  • Research
  • Resources
  • Statements
  • Uncategorized
  • Video

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS